Sanofi Makes $10 Million Strategic Investment in Vicore Pharma Holding

In The News
October 18, 2024

Ropes & Gray advised Sanofi in a $10 million strategic investment in Stockholm-based Vicore Pharma Holding AB. Vicore plans to use the funding for its Phase 2b trial investigating the disease-modifying potential of buloxibutid for patients suffering from the lung disease idiopathic pulmonary fibrosis. The transaction was announced on Sept. 30.

The Ropes & Gray team included life sciences licensing associate Daniel Freshman and life sciences licensing partner Abigail Gregor.